Australia's Neuren Pharmaceuticals rises to 1-1/2-year high on FDA Fast Track designation

Neuren Pharmaceuticals

20/10/2025 01:46

** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 10.7% to A$22.86, their highest level since May 28, 2024

** Stock on track for its strongest session since late-June, if current trend holds

** The U.S. Food and Drug Administration (FDA) granted Fast Track designation to co's drug for the treatment of Phelan-McDermid syndrome

** Fast Track designation has also been granted for NNZ-2591 in Angelman syndrome by FDA - co

** Stock up 79.6% YTD, including the day's move

 (Reporting by Shivangi Lahiri in Bengaluru)

 ((shivangi.lahiri@thomsonreuters.com))